Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants . Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer . Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Drug Metabolite | Products > Signaling Pathways > Aquaporin | Products > Signaling Pathways > Cadherin
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.